Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Area of Science:

• Oncology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) offer improved cancer treatment efficacy over traditional chemotherapy.
• However, acquired resistance to TKIs remains a significant clinical challenge, limiting long-term patient benefit.

Purpose of the Study:

• To review approved generations of TKIs and their associated resistance mechanisms.
• To highlight TKIs targeting BCR-ABL, EGFR, ALK, and BRAF/MEK pathways.

Main Methods:

• Literature review of approved TKIs and resistance mechanisms.
• Focus on specific kinase targets implicated in cancer therapy.

Main Results:

• Multiple TKI generations have been developed, targeting diverse oncogenic alterations.
• Common resistance mechanisms include kinase domain mutations, gene amplification, and pathway alterations.
• Emerging resistance to newer TKIs necessitates continuous drug development.

Conclusions:

• Understanding TKI resistance is key to advancing targeted cancer therapy.
• Ongoing research into novel TKIs and combination strategies is essential to overcome resistance.
• This review provides insights into TKI evolution and resistance patterns for BCR-ABL, EGFR, ALK, and BRAF/MEK inhibitors.